Skip to main
DGX
DGX logo

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 27 analyst ratings
Buy
Strong Buy 26%
Buy 19%
Hold 48%
Sell 4%
Strong Sell 4%

Bulls say

Quest Diagnostics Inc. demonstrates a strong growth trajectory, as evidenced by a 14.5% year-over-year revenue increase to $2.62 billion, with organic growth contributing approximately 5%. The company is capitalizing on the robust demand for consumer-initiated testing, with revenue soaring nearly 50% in the fourth quarter and reaching approximately $100 million for the fiscal year, further supported by an expanding test menu. Additionally, the firm is poised for continued financial improvement, including expectations for operating margin expansion in 2025 and solid cash flow from operations forecasted at $1.45 billion.

Bears say

Quest Diagnostics Inc. faces significant financial headwinds, including an approximate impact of $0.70 per share due to investments in modernizing its IT infrastructure and increased year-over-year interest expenses. The company's reliance on clinical testing, which generates over 95% of its revenue, may be adversely affected by these operational costs and regulatory preparations. Additionally, despite some positive prospects from advanced diagnostics, the mixed hospital backdrop may not sufficiently offset the challenges posed by these financial constraints.

Quest Diagnostics (DGX) has been analyzed by 27 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 19% recommend Buy, 48% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Buy based on their latest research and market trends.

According to 27 analysts, Quest Diagnostics (DGX) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.